Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials

Sleep Medicine Reviews

Volumn 16, Issue 5, 2012, Pages 431-443

  Boscolo Berto, Rafael ^a   Viel, Guido ^a   Montagnese, Sara ^a   Raduazzo, Daniella I ^a   Ferrara, Santo D ^a   Dauvilliers, Yves ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Cataplexy; Gamma hydroxybutyrate; GHB; Meta analysis; Narcolepsy; Randomized controlled trials; RCT; Sodium oxybate; Systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; DEXAMPHETAMINE; HYPNOTIC AGENT; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; PLACEBO; PROPRANOLOL;

AROUSAL; CATAPLEXY; CLINICAL GLOBAL IMPRESSION CHANGE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DAYTIME SOMNOLENCE; DRUG EFFICACY; EMBASE; EPWORTH SLEEPINESS SCALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPNAGOGIC HALLUCINATION; MEDLINE; META ANALYSIS; NARCOLEPSY; PARASOMNIA; POLYSOMNOGRAPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REM SLEEP; REVIEW; RISK; SYSTEMATIC REVIEW; WAKEFULNESS;

ADULT; CATAPLEXY; GABA-B RECEPTOR AGONISTS; HUMANS; NARCOLEPSY; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP; SLEEP STAGES; SODIUM OXYBATE;

EID: 84865193134     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2011.09.001     Document Type: Review

References (45)

1. Dauvilliers Y., Arnulf I., Mignot E. Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
2. Shouse M.N., Mahowald M.W. Epilepsy, sleep, and sleep disorders. Principles and Practice of Sleep Medicine 2005, 865-873. Elsevier Saunders, Philadelphia. 4th edition. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
3. Partinen M., Hublin C. Epidemiology of sleep disorders. Principles and practice of sleep medicine 2005, 631-635. Elsevier Saunders, Philadelphia. 4th edition. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
4. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997, 51:337-361.
5. Robinson D.M., Keating G.M. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs 2007, 21:337-354.
6. Gallimberti L., Canton G., Gentile N., Ferri M., Cibin M., Ferrara S.D., et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989, 2:787-789.
7. Russell I.J., Perkins A.T., Michalek J.E. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009, 60:299-309.
8. Food and Drug Administration. Accessed September 10th, 2010. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseacti on=Search.DrugDetails.
9. European Medicines Agency. Accessed September 10th, 2010. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici nes/000593/human_med_001163.jsp&murl=menus/medicines/medicines.jsp&mid=W C0b01ac058001d124.
10. Wise M.S., Arand D.L., Auger R.R., Brooks S.N., Watson N.F. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30:1712-1727.
11. Billiard M., Dauvilliers Y., Dolenc-GroŠelj L., Lammers G.J., Mayer G., Sonka K. Management of narcolepsy in adults. European Handbook of Neurological Management 2010, 513-528. Wiley-Blackwell, Oxford. 2nd Edition. N.E. Gilhus, M.P. Barnes, M. Brainin (Eds.).
12. Billiard M., Bassetti C., Dauvilliers Y., Dolenc-Groselj L., Lammers G.J., Mayer G., et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006, 13:1035-1048.
13. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, et al. Levels of evidence. Oxford centre for evidence-based medicine (): Accessed September 2010. http://www.cebm.net/index.aspx?o=1025.
14. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
15. Clarke M., Horton R. Bringing it all together: Lancet-Cochrane collaborate on systematic reviews. Lancet 2001, 357:1728.
16. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
17. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.
18. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
19. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
20. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
21. Lammers G.J., Arends J., Declerck A.C., Ferrari M.D., Schouwink G., Troost J. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993, 16:216-220.
22. Scrima L., Hartman P.G., Johnson F.H., Hiller F.C. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989, 26:331-343.
23. Scrima L., Hartman P.G., Johnson F.H., Thomas E.E., Hiller F.C. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990, 13:479-490.
24. Black J., Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006, 29:939-946.
25. Weaver T.E., Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep 2006, 29:1189-1194.
26. Xyrem Int Study G A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002, 25:42-49.
27. Xyrem Int Study G A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005, 1:391-397.
28. Xyrem Int Study G. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005, 6:415-421.
29. Black J., Pardi D., Hornfeldt C.S., Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 2009, 10:829-835.
30. Scrima L., Johnson F.H., Thomas E.E., Hiller F.C. Effects of Gamma-Hydroxybutyrate (GHB) on multiple sleep latency test (MSLT) in narcolepsy patients: a long term study (Abstract). Sleep Res 1990, 19:288.
31. Xyrem Int Study G Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004, 5:119-123.
32. Mamelak M., Black J., Montplaisir J., Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004, 27:1327-1334.
33. Xyrem Int Study G A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003, 26:31-35.
34. Broughton R., Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci 1980, 7:23-31.
35. Scharf M.B., Brown D., Woods M. The effects and effectiveness of î⊃3-hydroxybutyrate in patients with narcolepsy. Journal of Clinical Psychiatry 1985, 46:222-225.
36. Broughton R., Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979, 6:1-6.
37. Scrima L. Gamma-Hydroxybutyrate (GHB) treated narcolepsy patients continue to report cataplexy controlled for up to five (5) years (Abstract). Sleep Res 1992, 21:262.
38. Scrima L., Skakich-Scrima S., Miller B.R. The efficacy of Gamma-Hydroxybutyrate (GHB) in narcoleptics: 9 years (Abstract). Sleep 2000, 23:A293.
39. Xyrem Int Study G The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003, 41:131-135.
40. Mamelak M., Scharf M.B., Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. a review of clinical and sleep laboratory findings. Sleep 1986, 9:285-289.
41. Carskadon M.A., Rechtschaffen A. Monitoring and staging human sleep. Principles and Practice of Sleep Medicine 2005, 1362-1371. Elsevier Saunders, Philadelphia. 4th edition. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
42. Raynal D.M. Polygraphic aspects of narcolepsy. Narcolepsy 1976, 669-684. Spectrum, New York. C. Guilleminault (Ed.).
43. Dauvilliers Y., Paquereau J., Bastuji H., Drouot X., Weil J.S., Viot-Blanc V. Psychological health in central hypersomnias: the French Harmony study. J Neurol Neurosurg Psychiatry 2009, 80:636-641.
44. Plazzi G., Serra L., Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008, 12:109-128.
45. Montplaisir J., Billiard M., Takahashi S., Bell I.R., Guilleminault C., Dement W.C. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978, 13:73-89.